Navigation Links
Pravastatin Launched by Watson Pharmaceuticals

Pravastatin sodium has been launched by Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, under a distribution agreement with Bristol-Myers Squibb Company. Shipments of pravastatin sodium tablets// have been started by Watson, in the 10, 20 and 40 mg strengths.

Watson Pharmaceuticals, Inc. has its headquarters in Corona, CA. It is a leading specialty pharmaceutical company that specializes in the development, manufacture, marketing, and distribution of brand and generic pharmaceutical products. Watson owes its remarkable growth to the company’s strategy of combining internal product development along with strategic alliances and synergistic acquisitions of products and businesses.

This Pravastatin sodium is the authorized generic version of Bristol-Myers Squibb's Pravachol(R) product. It consumption has been recommended along with the diet to decrease risks of first heart attack in patients with cardiovascular risks such as elevated cholesterol. It has also been recommended to prevent recurrent heart attack or a stroke in patients with cardiovascular disease especially when diet and exercise are not enough to reverse the symptoms of the disease.

In the year 2005 Pravachol(R) produced sales of approximately $1.7 billion, according to IMS Health data.
'"/>




Page: 1

Related medicine news :

1. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
2. Nutrient Profiling System Launched By Food Officials in UK
3. New Oat And Soy-Based Fat Replacer Launched
4. Race Based Genome Project Launched By Mexico
5. Action Plan Against Drug Deaths Launched
6. New Fund Launched To Help HIV Positive Women
7. Use Of Viread Spreads As New Anti-AIDS Site Is Launched
8. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
9. Unique Smoking Helpline Launched In Manchester
10. Unique Smoking Helpline Launched In Manchester
11. New Home-Fertility Kit Launched For Men
Post Your Comments:
(Date:12/2/2008)...oday, advocates for teen,dating violence educatio...iz,Claiborne Inc. to launch ,MADE, -- Moms and Da...nd Chris Burke, educators and parents of Lindsay A...iend, are joining efforts with Liz,Claiborne Inc....hat will,consist of parents, teachers and concern...
(Date:12/2/2008)...erts say , , TUESDAY, Dec. 2 (HealthDay ... prevent cardiac arrest and deaths in critically i...s. , "Many hospitals have implemented these tea... Paul S. Chan, a cardiologist at the Mid America H...s had shown that rapid response teams may decrease...
(Date:12/2/2008)...l about 13 years younger than their chronological ...rthcoming in the Journals of Gerontology: Psychol...onses of 516 men and women age 70 and older who pa... their perceptions about age and their satisfactio...People generally felt quite a bit younger than the...
(Date:12/2/2008)...ire-USNewswire/ -- Students interested in nursing ...he N.C. Nurse Scholars Program (NSP) for the 2009-...CFNC.org. Approximately 400 new awards are availa...rolina State Education Assistance Authority (NCSEA... 1989 to address the dwindling supply of qualified...
Breaking Medicine News(10 mins):Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 2Health News:Parents of Murdered Dating Violence Victim, Legislators, and Teachers Unite to Launch 'MADE' - Moms and Dads for Education to Stop Teen Dating Abuse 3Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 3Health News:Old as you want to be: Study finds most seniors feel younger 2Health News:N.C. Nursing Scholarship Applications Due February 28 for Bachelor's Degrees, May 3 for Associate and Graduate Degrees 2
...fer bouts of nausea and vomiting during their preg...but it but it seems that going through morning sic...s who have conducted a new study and found that wo...s have a 30 percent lower risk of developing breas...
...s smoking rate has shown a decline, thanks to the ... to kick the habit. The statistics in the 2006 re...n comparison to 2002 figures. Over the past year, ...2.5% to 19.9%) and among Hispanics (from 20.2% to ...
...cular on switch triggers gene activity that cause...ties to glucose production in the liver was disco... hospital . The on switch, a protein called CREB...hat binds to a section of DNA near a gene and trig...
...amil Nadu, who allegedly tried to get his 15-year-...erform a caesarean operation , today said the accu... Dr. Murugan rubbished the media reports that he m...leepan Raj, a tenth standard student, operating on...
Other Medicine News:Health News:Morning Sickness may Signify Lower Breast Cancer Risk 2Health News:Morning Sickness may Signify Lower Breast Cancer Risk 3Health News:New York Records Decline in Smoking Rate 2Health News:Research Studies on Molecular Switches of Gene 2
(Date:12/1/2008)...stCall/ -- GeoVax Labs, Inc.,(OTC Bulletin Board:...eloping,human vaccines for diseases caused by HIV...tious agents, announced today that the launch of i...in twelve sites across North and South America.,T...e National Institutes of,Health (NIH), and the HI...
(Date:11/30/2008)...Newswire-USNewswire/ -- Older adults who exercise ... greater number of small blood vessels in the brai...nual meeting of the Radiological Society of North ...t the University of North Carolina ( UNC) - Chap...lder adults who exercise to brain scans of those w...
(Date:11/28/2008)... 28 German biotech company,Partec... HIV monitoring and,AIDS patient follow-up diagno...he year 2008, 2.5 million patient tests have been ...fordable "CyFlow" system, supporting already,more...o introduction of the,Partec innovation, the aver...
(Date:11/27/2008)... acute lymphoblastic leukemia relapse cases arise ...is , , MEMPHIS, Tenn., Nov. 27 /PRNewswire-...esearch Hospital have identified distinctive genet...ute lymphoblastic leukemia (ALL) that cause relaps...ments for ALL relapse in children and, ultimately,...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Women Mexican Americans at higher risk of ruptured brain aneurysm 21637 1Women Mexican Americans at higher risk of ruptured brain aneurysm 21637 2Women Mexican Americans at higher risk of ruptured brain aneurysm 21637 3Notification of Annual General Meeting and Extraordinary General Meeting 21635 1Notification of Annual General Meeting and Extraordinary General Meeting 21635 2National Staff Nurses Union Endorses Obama for President 3B UAN Leaders Cite Obamas Commitment to Working Families Health Care Solutions 21630 1National Staff Nurses Union Endorses Obama for President 3B UAN Leaders Cite Obamas Commitment to Working Families Health Care Solutions 21630 2Palladian Muscular Skeletal Health 28formerly Prism Health Networks 29 to Promote Collaborative Expanded Practice Model at Major Insurance Conferenc 5945 1Palladian Muscular Skeletal Health 28formerly Prism Health Networks 29 to Promote Collaborative Expanded Practice Model at Major Insurance Conferenc 5945 2
... 21, 2007 - Medical,professionals seeking to treat...red gram-negative pneumonia may have a new weapon:...andidate being,developed by Nektar Therapeutics (N... evaluating the use of,NKTR-061 (Inhaled Amikacin)...spital-acquired gram-negative pneumonia were,prese...
...RK, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGe...,the publication of new clinical data relevant to ...rringtonine). The paper "Targeted,therapy and the ...,by researchers Simona Soverini and colleagues at ...lume 92, pages 401-404) offers,insight into the gr...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
GE Healthcare is known as an innovator in best-in-class analysis programs for every major care area monitoring device. With advanced programs such as 12SL, Gender-Specific, and ACI-TIPI, GE can help
For use in vitreo-retinal procedures with a non contact system, and compatible with the Oculus BIOM system, this lens delivers the highest image clarity available in a non contact surgical lens.
The Affinity pacemaker family offers some of today's smallest, truly automatic devices. Featuring the most effective combination of advanced technologies ever seen, the Affinity DR pacemaker incorpor
The IsoFlex lead family features St. Jude Medical's premier passive-fixation pacing leads. The lead is available in both polyurethane (IsoFlex P lead) and silicone (IsoFlex S lead) models, atrial J a
Medicine Products: